United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 5

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 5 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderSutro Biopharma · 54

Strongest available path4D Molecular Therapeutics · -51.2%

Widest latest marginAtara Biotherapeutics · 27.1%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1STRO · NASDAQ

Sutro Biopharma

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2003San Francisco, California$339.1M market cap

View full Companies Radar profile

54Moderate

Snapshot price$20.45as of page date

Monthly-close return-90.2%five-year window

FY2025 revenue$0.10BSUTRO BIOPHARMA, INC.

Net margin-186.5%FY2025

P/E snapshot-3.3xone ratio, not a verdict

Prism attention16.1%share across these five

Filing track recordRevenue, USD billions

+65.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.4%

52-week position36% through range

$7.15$43.85

News mentions916

Community mentions0partial coverage

U.S.-scope patents469

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position0/100
Capital-event signal64/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2RXRX · Nasdaq

Recursion

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013New York$1.79B market cap

View full Companies Radar profile

45Cautious

Snapshot price$3.34as of page date

Monthly-close return-86.4%five-year window

FY2025 revenue$0.07BRECURSION PHARMACEUTICALS, INC.

Net margin-863.4%FY2025

P/E snapshot-3.7xone ratio, not a verdict

Prism attention39.4%share across these five

Filing track recordRevenue, USD billions

+633.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 64.6%

52-week position13% through range

$2.77$7.18

News mentions2.3K

Community mentions0partial coverage

U.S.-scope patents247

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position13/100
Capital-event signal75/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3IPSC · Nasdaq

Century Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2018Philadelphia, Pennsylvania$366.7M market cap

View full Companies Radar profile

44Cautious

Snapshot price$2.02as of page date

Monthly-close return-91.0%five-year window

FY2025 revenue$0.11BCentury Therapeutics, Inc.

Net margin-8.8%FY2025

P/E snapshot-4.5xone ratio, not a verdict

Prism attention10.2%share across these five

Filing track recordRevenue, USD billions

+1999.7%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 175.9%

52-week position61% through range

$0.43$3.04

News mentions580

Community mentions2partial coverage

U.S.-scope patents102

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ATRA · Nasdaq

Atara Biotherapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2021San Francisco, California$92.3M market cap

View full Companies Radar profile

43Cautious

Snapshot price$9.20as of page date

Monthly-close return-97.5%five-year window

FY2025 revenue$0.12BAtara Biotherapeutics, Inc.

Net margin27.1%FY2025

P/E snapshot5.9xone ratio, not a verdict

Prism attention25.1%share across these five

Filing track recordRevenue, USD billions

+1308.7%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 275.3%

52-week position35% through range

$3.92$19.14

News mentions1.4K

Community mentions22partial coverage

U.S.-scope patents84

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal40/100
Management stability90/100
Market position9/100
Capital-event signal74/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 9 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5FDMT · Nasdaq

4D Molecular Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Emeryville, California$810.4M market cap

View full Companies Radar profile

40Cautious

Snapshot price$14.67as of page date

Monthly-close return-51.2%five-year window

FY2025 revenue$0.09B4D Molecular Therapeutics, Inc.

Net margin-164.4%FY2025

P/E snapshot-3.6xone ratio, not a verdict

Prism attention9.2%share across these five

Filing track recordRevenue, USD billions

+372.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 47.4%

52-week position79% through range

$5.97$16.93

News mentions525

Community mentions4partial coverage

U.S.-scope patents246

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal38/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

4D Molecular Therapeutics

-51.2%

Recursion

-86.4%

Sutro Biopharma

-90.2%

Century Therapeutics

-91.0%

Atara Biotherapeutics

-97.5%

Latest revenue

USD billions, official filing scope shown on each company card.

Atara Biotherapeutics

$0.12B

Century Therapeutics

$0.11B

Sutro Biopharma

$0.10B

4D Molecular Therapeutics

$0.09B

Recursion

$0.07B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Atara Biotherapeutics

27.1%

Century Therapeutics

-8.8%

4D Molecular Therapeutics

-164.4%

Sutro Biopharma

-186.5%

Recursion

-863.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Recursion

39.4%

Atara Biotherapeutics

25.1%

Sutro Biopharma

16.1%

Century Therapeutics

10.2%

4D Molecular Therapeutics

9.2%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Recursion leads the conversation

It holds 39.4% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.07B.

Price path

4D Molecular Therapeutics leads the available price paths

Its monthly-close return is -51.2% for the five-year window. At the other end, Atara Biotherapeutics is -97.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Atara Biotherapeutics has the widest latest margin

Its FY2025 net margin is 27.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Century Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -4.5x while its five-year window price return is -91.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · STRO

Sutro Biopharma

916available Prism news records

Prism top themes

Capital allocation & transactions

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-12.7%117 latest 12m vs 134 prior 12m

Machine-classified coverage tone

90.8% positive-1.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

adc therapeutics 56cancer biomarkers 18stock price 10stock performance 9angiogenesis inhibitors 8share price 7stock surge 5vaccine candidate selection 5

Keyword tag occurrences in available Prism news records.

Coverage: 2010-11-17–2026-06-11 · trend and themes shown through 2026-06

Areas of research · RXRX

Recursion

2,254available Prism news records

Prism top themes

Price action & investor response

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-26.9%351 latest 12m vs 480 prior 12m

Machine-classified coverage tone

90.9% positive-1.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

drug repurposing ai 156machine learning drug discovery 107neural networks drug design 91ai toxicity prediction 51drug design 51deep learning biology 47pharmacogenomics 37ai screening 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · ATRA

Atara Biotherapeutics

1,429available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+4.7%199 latest 12m vs 190 prior 12m

Machine-classified coverage tone

80.4% positive-14.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cell-based therapies 25gene therapy rare diseases 21stock performance 14relapsed hodgkin's immunotherapy 9cell therapy 9immunotherapy 9rare disease treatment 8stem cell banking 7

Keyword tag occurrences in available Prism news records.

Coverage: 2012-10-26–2026-05-26 · trend and themes shown through 2026-05

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

STRO

Sutro Biopharma

through 2026-03-23

Company announcements 8Earnings releases 5Leadership changes 4Regulatory 4Business contracts 1

2026-03-23
Earnings releases
Revenue was $102.5 million for the year ended December 31, 2025.
2025-12-17
Regulatory
On December 17, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of December 16, 2025 the Company’s common stock has maintained an average closing share price of at least $1.00 following the Company’s 1:10 reverse stock split that became effective on December 3, 2025. The Company’s shares are no longer considered to be below the minimum bid price requirement of Rule 5450(a)(1), and as a result the Company has regained compliance with the Nasdaq continued listing standard.
2025-09-30
Company announcements
Sutro Biopharma, Inc. (NASDAQ: STRO) confirmed on Monday that it will undergo a significant restructuring process designed to extend its cash runway through at least the middle of 2027.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RXRX

Recursion

through 2026-02-27

Earnings releases 24Leadership changes 13Company announcements 9M&A 7Listing / IPO 2

2026-02-27
M&A
In recent days, his firm acquired a significant amount of shares from Recursion Pharmaceuticals, a biotechnology company that uses artificial intelligence to accelerate
2026-02-25
Earnings releases
We ended the year with $754 million in cash.
2025-11-21
Leadership changes
Current CEO Chris Gibson, one of the founders of the company, announced earlier this month that he would step down, telling STAT that Recursion, which is moving toward later-stage development programs, needed a leader with a different skill set. Gibson is becoming board chair.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IPSC

Century Therapeutics

through 2025-04-07

Earnings releases 8Leadership changes 4

2025-04-07
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Century Therapeutics $6.59 million 5.73 -$136.67 million ($1.63) -0.27
2023-04-12
Leadership changes
Dr. Russotti, who has served as the Company’s Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Company’s Board of Directors to pursue other opportunities.
2025-03-29
Earnings releases
Chardan Capital also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.64) EPS.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ATRA

Atara Biotherapeutics

through 2026-03-25

Earnings releases 7Leadership changes 6Company announcements 2Asset acquisitions 1Lawsuits 1

2026-03-25
Lawsuits
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Atara Biotherapeutics, Inc. securities between May 20, 2024 and January 9, 2026.
2025-09-04
Leadership changes
In addition to his role as Chair of the Board, Greg will also serve as a member of the Nominating and Corporate Governance Committee.
2025-05-15
Earnings releases
Total revenues were $98.1 million for the first quarter 2025, as compared to $27.4 million for the same period in 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FDMT

4D Molecular Therapeutics

through 2026-01-10

Leadership changes 4Earnings releases 2Listing / IPO 1

2026-01-10
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4D Molecular Therapeutics $40,000.00 10,711.88 -$160.87 million ($3.75) -2.00
2025-11-17
Leadership changes
4D Molecular has hired Kristian Humer as the late-stage biotechnology company's new chief financial officer.
2023-05-05
Listing / IPO
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 21–28. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Sutro Biopharma leads the readiness ranking

Its Prism readiness score is 54/100, the highest in this five-company comparison.

Open Sutro Biopharma in Companies Radar

Scale and margin leadership sit with Atara Biotherapeutics and Atara Biotherapeutics

Atara Biotherapeutics has the largest displayed latest revenue at $0.12B; Atara Biotherapeutics has the widest displayed latest margin at 27.1%.

Open Atara Biotherapeutics in Companies Radar

Comparisons

Strongest versus weakest available price path

4D Molecular Therapeutics is -51.2% for its five-year window; Atara Biotherapeutics is -97.5% for its five-year window.

Open 4D Molecular Therapeutics in Companies Radar Open Atara Biotherapeutics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.12B for Atara Biotherapeutics to $0.07B for Recursion. Entity and filing-period labels remain visible on the company cards.

Open Atara Biotherapeutics in Companies Radar Open Recursion in Companies Radar

Anomalies

Atara Biotherapeutics has the widest attention-readiness rank gap

It ranks #2 by measured news attention (25.1%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Atara Biotherapeutics in Companies Radar

Century Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1999.7% while its available monthly-close return is -91.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Century Therapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Recursion's 39.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Recursion in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Sutro Biopharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 54/100 score.

Open Sutro Biopharma in Companies Radar

Stress-test the largest divergence before forming a view

Compare Century Therapeutics's profile with 4D Molecular Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Century Therapeutics in Companies Radar Open 4D Molecular Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.